Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2013 Healthcare Conference

Jean-Jacques Bienaime, CEO of BioMarin, to Present at the Credit Suisse 2013
Healthcare Conference

SAN RAFAEL, Calif., Nov. 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive
Officer at BioMarin, will present a company update at the Credit Suisse 2013
Healthcare Conference on Tuesday, November 12, 2013 at 9:30 a.m. MST.
Interested parties may access a live audio webcast of the conference call via
the investor section of the BioMarin website, www.BMRN.com. A replay of the
call will be archived on the site for at least one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis
I (MPS I), a product which BioMarin developed through a 50/50 joint venture
with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for
phenylketonuria (PKU), developed in partnership with Merck Serono, a division
of Merck KGaA of Darmstadt, Germany; and Firdapse® (amifampridine), which has
been approved by the European Commission for the treatment of Lambert Eaton
Myasthenic Syndrome (LEMS). Product candidates include Vimizim™
(N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which
successfully completed Phase 3 clinical development for the treatment of MPS
IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is
currently in Phase 3 clinical development for the treatment of PKU, BMN 673, a
poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 3
clinical development for the treatment of germline BRCA breast cancer, BMN
701, a novel fusion of acid alpha glucosidase (GAA) with a peptide derived
from insulin like growth factor 2, which is currently in Phase 1/2 clinical
development for the treatment of Pompe disease, BMN 111, a modified
C-natriuretic peptide, which is currently in Phase 1 clinical development for
the treatment of achondroplasia and BMN 190, a recombinant human tripeptidyl
peptidase-1 (rhTPP1) for the treatment of late-infantile neuronal ceroid
lipofuscinosis (CLN2), a form of Batten Disease. For additional information,
please visit www.BMRN.com. Information on BioMarin's website is not
incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of
BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

CONTACT: Investors:
         Traci McCarty
         BioMarin Pharmaceutical Inc.
         (415) 455-7558
        
         Media:
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.